# TROPIC (NCT00417079)

> XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: cabazitaxel
- Indication: metastatic castration-resistant prostate cancer after docetaxel treatment

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00417079
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Sanofi
- Conditions: Neoplasms; Prostatic Neoplasms
- Interventions: cabazitaxel (XRP6258) (RPR116258); mitoxantrone; prednisone
- Enrollment: 755
- Primary outcome: Overall Survival

## Indexed commentary on TROPIC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 8 posts on X
- 7 podcast episodes
- 3 YouTube videos

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tropic-nct00417079

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00417079", "email": "<work email>"}; the inbox owner confirms by the emailed link.